Loading...
•
Jun 30, 2021
Trevena Q2 2021 Earnings Report
Reported a net loss due to increases in commercialization activities for OLINVYK.
Key Takeaways
Trevena reported a net loss of $14.0 million for the second quarter of 2021, driven by increased commercialization activities for OLINVYK. Cash and cash equivalents were $91.0 million as of June 30, 2021, expected to fund operations through YE 2022.
Sales team made progress with hospital formularies on the OLINVYK launch.
Initiated respiratory physiology study in elderly / obese subjects, with topline data expected by year-end 2021.
Jiangsu Nhwa Pharmaceutical, Trevena’s partner in China, enrolled the first patient in their Phase 3 trial for OLINVYK.
TRV045 IND filing for diabetic neuropathic pain on track for Q3.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...